PlainRecalls
FDA Drug Low Class III Terminated

Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30), b) 90 count blister (NDC 66582-321-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889

Reported: May 14, 2014 Initiated: January 13, 2014 #D-1310-2014

Product Description

Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30), b) 90 count blister (NDC 66582-321-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889

Reason for Recall

This recall of LIPTRUZET is being initiated due to packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.

Details

Recalling Firm
Merck & Co Inc
Units Affected
20,259 cartons
Distribution
Nationwide and Puerto Rico
Location
Whitehouse Station, NJ

Frequently Asked Questions

What product was recalled?
Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30), b) 90 count blister (NDC 66582-321-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889. Recalled by Merck & Co Inc. Units affected: 20,259 cartons.
Why was this product recalled?
This recall of LIPTRUZET is being initiated due to packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.
Which agency issued this recall?
This recall was issued by the FDA Drug on May 14, 2014. Severity: Low. Recall number: D-1310-2014.